Page last updated: 2024-10-17

n(1)-methylnicotinamide and Ovarian Neoplasms

n(1)-methylnicotinamide has been researched along with Ovarian Neoplasms in 1 studies

N(1)-methylnicotinamide: RN given refers to parent cpd
1-methylnicotinamide : A pyridinium ion comprising nicotinamide having a methyl group at the 1-position. It is a metabolite of nicotinamide which was initially considered to be biologically inactive but has emerged as an anti-thrombotic and anti-inflammatory agent.

Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Kilgour, MK1
MacPherson, S1
Zacharias, LG1
Ellis, AE1
Sheldon, RD1
Liu, EY1
Keyes, S1
Pauly, B1
Carleton, G1
Allard, B1
Smazynski, J1
Williams, KS1
Watson, PH1
Stagg, J1
Nelson, BH1
DeBerardinis, RJ1
Jones, RG1
Hamilton, PT1
Lum, JJ1

Other Studies

1 other study available for n(1)-methylnicotinamide and Ovarian Neoplasms

ArticleYear
1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer.
    Science advances, 2021, Volume: 7, Issue:4

    Topics: Ascites; Female; Humans; Niacinamide; Ovarian Neoplasms; Tumor Microenvironment

2021